Immuneering CorporationIMRXNASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank33
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Latest
$-45.49M
↓ 30% vs avg
Percentile
P33
Within normal range
Streak
1 yr
Consecutive growthContracting
Average
$-34.97M
Historical baseline
PeriodValueYoY Change
TTM$-45.49M+17.4%
2024$-55.08M-11.7%
2023$-49.31M-10.0%
2022$-44.84M-45.1%
2021$-30.91M-110.7%
2020$-14.67M-228.8%
2019$-4.46M-